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Recombinant envelope geneDuring feline leukemia virus (FeLV) infection in the domestic cat, viruses with a novel envelope gene arise by
recombination between endogenous FeLV-related elements and the exogenous infecting species. These
recombinant viruses (FeLV-B) are of uncertain disease association, but have been linked to the induction of
thymic lymphoma. To assess the role of FeLV-B in the induction of multicentric lymphoma and other non-T-cell
disease, the frequency of occurrence and nature of FeLV-B were examined in diseased tissues from a large
collection of FeLV-infected animals. Diseased tissues were examined by Southern blot and PCR ampliﬁcation to
detect the presence of FeLV-B. Further analysis was performed to establish the recombination junctions and
infectivity of FeLV-B in diseased tissues. The results conﬁrmed the frequent association of FeLV-B with thymic
lymphoma but showed infrequent generation, low levels and lack of infectivity of FeLV-B in non-T-cell diseases
including multicentric lymphoma.Immunology, TulaneUniversity
ns, LA 70112, USA. Fax:+1 504
llevy@tulane.edu (L.S. Levy).
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Feline leukemia virus (FeLV) is a naturally occurring, horizontally
transmitted gammaretrovirus associated with malignant, proliferative
and degenerative diseases in the domestic cat. FeLV occurs in nature not
as a single genomic species but as a genetically complex family of closely
related viruses. Genetic variation in FeLV is generated during virus
replication through error-prone reverse transcription and by recombi-
nation with endogenous FeLV-related sequences in the domestic cat
genome. Such variation has led to four naturally occurring FeLV
subgroups, designated A, B, C, and T, that are distinguished genetically
by sequence differences in the surface glycoprotein gene (SU) and
functionally by interactionwithdistinct host cell receptors for entry. The
weakly pathogenic FeLV subtype A (FeLV-A) is thought to represent the
predominant agent spread horizontally cat-to-cat in nature, fromwhich
FeLV-B, -C and -T arise de novo in the infected animal by envelope (env)
gene recombination, mutation or insertion events (Levy, 2008; Over-
baugh and Bangham, 2001).While FeLV-A is associated with prolonged
asymptomatic infection in the cat that may lead to malignant disease,
typically a T-cell lymphoma of the thymus (Neil et al., 1991; Rezanka
et al., 1992), the FeLV-B, -C and -T subgroups facilitate and/or redirectdisease outcome to lymphoma, anemia or immunodeﬁciency disease,
respectively (Levy, 2008; Overbaugh and Bangham, 2001).
Of particular interest in the present study is the generation of
FeLV-B, a polytropic virus that arises by recombination in vivo
between the infecting exogenous species and endogenous FeLV-
related sequences in the cat genome. As a consequence of recombi-
nation, FeLV-B viruses contain a novel env gene with SU sequences
containing variable representation of endogenous FeLV-derived DNA
(Neil et al., 1991; Roy-Burman, 1995; Stewart et al., 1986). The
endogenous, FeLV-related elements in the domestic cat occur at 9–16
copies per haploid genome (Pontius et al., 2007; Roca et al., 2005),
differ in load among domestic cats of different breeds (Tandon et al.,
2007) and represent a genetic set of ﬂuid, polymorphic composition
(Roca et al., 2004). The endogenous FeLV-related elements are
defective and do not encode infectious particles, although some
elements remain transcriptionally active and may be expressed in
leukemic cells and in lymphoid tissues from healthy animals
(McDougall et al., 1994; Roy-Burman, 1995). Recombination between
endogenous and exogenous FeLV env sequences is thought to occur in
a manner analogous to the generation of MCF recombinant viruses
during MuLV infection (Fan, 1997). Unlike MCF viruses, which are
known to represent the proximal leukemogen inMuLV infection (Fan,
1997), the disease association of FeLV-B infection remains unclear.
While FeLV-B can be identiﬁed in 30%–50% of natural infections,
always in conjunction with FeLV-A (Coelho et al., 2008; Neil et al.,
1991; Roy-Burman, 1995), FeLV-B is overrepresented in the diseased
tissues of animals with lymphoma as compared to asymptomatic,
Fig. 1. Southern blot analysis of genomic DNA from tumor (T) or paired normal (N)
tissue from FeLV-infected cats O24, O26 and N91 bearing thymic lymphoma (TL) or
multicentric lymphoma (ML) (Chandhasin et al., 2005b). A. DNA samples (8 μg) were
digested with KpnI and hybridized to probe B/S, a Sau3A fragment from the env gene of
FeLV-B/Gardner-Arnstein speciﬁc for the major classes of endogenous FeLV that serve
as substrates for recombination. The distinctive hybridizing fragment of ∼3.6-kb (*)
indicates recombinant FeLV-B provirus in genomic DNA (Chandhasin et al., 2005b;
Tsatsanis et al., 1994). B. KpnI-digested DNA samples were also hybridized to a probe
representing the U3 region of the LTR of exogenous FeLV. By this analysis, clonally
integrated proviruses are visualized as host-virus junction fragments in tumor DNA
(Levy et al., 1984).
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lymphomas in particular (Jarrett, 1980, 1992; Roy-Burman, 1995;
Sheets et al., 1993; Tsatsanis et al., 1994). In a recent study, however,
FeLV-B recombinants were identiﬁed only infrequently by PCR or
Southern blot analysis in a set of unusual multicentric lymphomas of
B-cell origin induced experimentally by viruses containing the unique
sequence elements of a natural variant designated FeLV-945 (Chand-
hasin et al., 2005a). FeLV-945 had been identiﬁed originally in a
geographic and temporal cohort of naturally infected animals in
which non-T-cell disease, including multicentric lymphoma, was the
condition most commonly identiﬁed. As the predominant isolate in
non-T-cell diseases in the cohort, FeLV-945 was shown to contain
unique sequence elements in the LTR and SU gene. The substitution of
these elements into prototype FeLV-A signiﬁcantly reduced the
latency to disease and shifted the disease spectrum entirely to
recapitulate the multicentric lymphoma from which FeLV-945 was
originally identiﬁed (Chandhasin et al., 2005b). Considering the
relatively rapid disease induction in animals infected with chimeric
viruses containing elements of FeLV-945, the infrequent detection of
FeLV-B in preliminary analysis (Chandhasin et al., 2005a,b) suggested
that the generation of FeLV-B recombinants may not be involved in
the induction of multicentric lymphoma, or alternatively, may occur
infrequently or inefﬁciently when FeLV-945 is the exogenously
infecting species. To address this question further, the frequency of
occurrence and nature of FeLV-B recombinants was examined in a
large collection of diseased tissues from naturally and experimentally
infected cats. Twenty-two naturally infected animals were examined,
representing the geographic and temporal cohort fromwhich FeLV-945
was originally identiﬁed (Chandhasin et al., 2004; Levesque et al., 1990).
Twenty experimentally infected animals were examined from several
previous studies (Chandhasin et al., 2005a,b; Levy et al., 1988) in which
neonatal cats were inoculated with prototype FeLV-A/61E, with
chimeric viruses in which the unique LTR and/or SU gene of FeLV-945
were substituted into FeLV-A/61E, or with the myc oncogene-contain-
ing LC-FeLV isolate. Diseased tissues were examined by Southern blot
and PCR ampliﬁcation to detect the presence of FeLV-B. Further analysis
was performed to establish the recombination junctions and infectivity
of FeLV-B in diseased tissues.
Results and discussion
Demonstration of integrated FeLV-B proviral DNA in diseased tissues by
Southern blot
To evaluate the frequency with which integrated FeLV-B proviral
DNA could be detected in diseased tissues, large molecular weight
genomic DNA (8 μg) was digested with KpnI and examined by
Southern blot analysis. The blot was hybridized to probe B/S, a Sau3A
fragment from the env gene of FeLV-B/Gardner-Arnstein speciﬁc for
the major classes of endogenous FeLV that serve as substrates for
recombination (Chandhasin et al., 2005b; Tsatsanis et al., 1994).
Analysis revealed the 3.6-kb fragment distinctive of FeLV-B proviral
DNA in thymic lymphoma samples, but not in samples of multicentric
lymphoma or in uninvolved tissues of the same animals (Fig. 1A). By
comparison, hybridization of KpnI-digested DNA with a probe for the
LTR of exogenous FeLV clearly demonstrated the pattern of clonally
integrated proviruses distinctive of the monoclonal expansion in all
tumor samples examined, but not in uninvolved tissues of the same
animals (Fig. 1B). By applying this approach to the entire collection,
FeLV-B provirus was detected in the DNA of diseased tissues from 5 of
22 naturally infected animals, including 2 of 4 cases of thymic
lymphoma and 3 of 12 cases of multicentric lymphoma. FeLV-B was
not detected in myeloproliferative disease, mast cell leukemia, feline
infectious peritonitis, chronic glomerulonephritis, or in healthy, FeLV-
infected animals (Table 1). In experimentally infected animals, FeLV-B
was detected in 9 of 13 cases of thymic lymphoma and in twoadditional animals for which FeLV-B was included in the original
inoculum. FeLV-B was not detected by this measure in multicentric
lymphoma, in an animal inoculated with myc-containing FeLV in the
presence of FeLV-B in the inoculum, or in mock-infected animals
(Table 2). Considering all cases together, the incidence of FeLV-B in
thymic lymphoma (11 of 17) was signiﬁcantly higher than in
multicentric lymphoma (3 of 15) as measured by Fisher Exact Test
(p=0.015).
PCR ampliﬁcation of FeLV-B proviral DNA from diseased tissues
PCR ampliﬁcation was then used to validate the results and to
extend the ﬁndings to cases in which FeLV-B integrations may have
occurred at a frequency in the tumormass below the level of detection
by Southern blot analysis. Genomic DNA samples were ampliﬁed
using forward and reverse primers speciﬁc for the endogenous FeLV-
related CFE-6 element and exogenous FeLV-945, respectively. CFE-6
was selected for this purpose because it represents the major class of
nearly full-length proviruses in the cat genome and contains a
complete env gene with open reading frame (Kumar et al., 1989).
Table 1
Detection of FeLV-B proviral DNA in diseased tissues from a cohort of naturally infected
cats.a
Animal Diseaseb S. Blot PCR
922 Multicentric lymphoma − −
925 Multicentric lymphoma − −
934 Multicentric lymphoma − −
945 Multicentric lymphoma − −
1011 Multicentric lymphoma − −
1043 Multicentric lymphoma + +
1046 Multicentric lymphoma − −
1049 Multicentric lymphoma + +
1112 Multicentric lymphoma − −
1316 Multicentric lymphoma − −
1325 Multicentric lymphoma − −
1345 Multicentric lymphoma + +
931 Thymic lymphoma − −
1037 Thymic lymphoma + +
1100 Thymic lymphoma − −
1110 Thymic lymphoma + +
903 Myeloproliferative disease − −
905 Mast cell leukemia − −
924 Feline infectious peritonitis − −
1002 Chronic glomerulonephritis − −
936 Healthy, FeLV-negative − −
1223 Healthy, FeLV-infected − −
942 Healthy, FeLV-infected − −
a Presence (+) or absence (−) of FeLV-B proviral DNA as detected by Southern blot
analysis or polymerase chain reaction (PCR) ampliﬁcation.
b Tumor tissues were analyzed from animals with lymphoma. Mesenteric lymph
node, bone marrow, thymus or kidney was examined from animals 903, 905, 1223 or
942, respectively. Spleen was examined from animals 924, 1002 and 936.
Fig. 2. PCR ampliﬁcation of the recombinant env gene of FeLV-B from the genomic DNA
of naturally and experimentally infected cats. Genomic DNA samples were ampliﬁed by
PCR using forward and reverse primers speciﬁc for the endogenous FeLV-related CFE-6
element and exogenous FeLV-945, respectively. A. Genomic DNA was examined from
naturally occurring thymic lymphomas (1037 thy, 1110 thy and 1100 thy) and
multicentric lymphomas (1345 liver, 1049 spleen, and 945 kidney). B. Genomic DNA
was examined from experimentally induced thymic lymphomas (O26 thy, O24 thy, and
981-2 thy) and multicentric lymphomas (N90 liver, N91 liver, and N92 liver). Indicated
by the arrow is the predicted ampliﬁcation product of ∼1.1-kb. Genomic DNA from
uninfected FEA cells, and from canine D-17 cells infected with FeLV-B/Gardner-
Arnstein were examined as negative and positive controls, respectively.
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absence of a product from DNA of uninfected FEA cells and the ready
detection of a product of the predicted size (1.1-kb) from canine D-17
cells infected with FeLV-B/Gardner-Arnstein (indicated in Fig. 2 as
negative and positive control, respectively). When this strategy was
applied to the collection of diseased tissues from naturally infected
animals, the predicted ampliﬁcation product was detected from 2 of 4
cases of thymic lymphoma (50%) and 3 of 12 cases of multicentricTable 2
Detection of FeLV-B proviral DNA in diseased tissues from experimentally infected cats.a
Animal Diseaseb Inoculumc
O3 Thymic lymphoma FeLV-A/61E
O4 Thymic lymphoma FeLV-A/61E
O5 Thymic lymphoma FeLV-A/61E
O6 Thymic lymphoma FeLV-A/61E
O23 Thymic lymphoma 61E945L
O24 Thymic lymphoma 61E945L
O25 Thymic lymphoma 61E945L
O26 Thymic lymphoma 61E945L
981-2 Thymic lymphoma LC-FeLV (FeLV-A+B)
981-3 Thymic lymphoma LC-FeLV (FeLV-A+B)
J5-1 Thymic lymphoma LC-FeLV (FeLV-A+B)
N65 Thymic lymphoma 61E/945SL
N67 Thymic lymphoma 61E/945SL
N89 Unknown 61E/945SL
N90 Multicentric lymphoma 61E/945SL
N91 Multicentric lymphoma 61E/945SL
N92 Multicentric lymphoma 61E/945SL
586-4 Feline infectious peritonitis FeLV-A+B
585-2 Transient lymphadenopathy LC-FeLV (FeLV-A+B)
586-3 Healthy LC-FeLV (FeLV-A+B)
586-5 Healthy Mock
585-1 Healthy Mock
a Presence (+) or absence (−) of FeLV-B proviral DNA as detected by Southern blot ana
b Tumor tissues were analyzed from animals with lymphoma. Lymph node was examined
586-5. Lung, lymph node and liver was examined from N89.
c Animals were inoculated experimentally with FeLV-A/61E, a synthetic recombinant of FeLV
945 (61E/945SL), a naturalmyc-containing isolateof FeLV (LC-FeLV) in thepresenceofhelper vi
were inoculated intraperitoneally except N65 and N67, which were inoculated intradermally.lymphoma (25%) (Fig. 2A), thus recapitulating the ﬁndings from
Southern blot analysis (Table 1). Likewise consistent with the results
of Southern blot analysis, FeLV-B sequences were not detected in
myeloproliferative disease, mast cell leukemia, feline infectious
peritonitis, chronic glomerulonephritis, or in healthy, FeLV-infected
animals (Table 1). Thus, in the natural cohort in which FeLV-945
predominates, FeLV-B is identiﬁed in thymic lymphomas at a
frequency consistent with previous reports, but is relatively infre-
quent in non-T-cell diseases including multicentric lymphoma.
Application of the PCR strategy to diseased tissues of experimentallyReference S. Blot PCR
Chandhasin et al. (2005a,b) + +
Chandhasin et al. (2005a,b) + +
Chandhasin et al. (2005a,b) + +
Chandhasin et al. (2005a,b) + +
Chandhasin et al. (2005a,b) + +
Chandhasin et al. (2005a,b) + +
Chandhasin et al. (2005a,b) + +
Chandhasin et al. (2005a,b) + +
Levy et al. (1988) − −
Levy et al. (1988) + +
Levy et al. (1988) − −
Chandhasin et al. (2005a,b) − +
Chandhasin et al. (2005a,b) − +
Chandhasin et al. (2005a,b) − ±
Chandhasin et al. (2005a,b) − ±
Chandhasin et al. (2005a,b) − ±
Chandhasin et al. (2005a,b) − ±
Levy et al. (1988) + +
Levy et al. (1988) − +
Levy et al. (1988) + +
Levy et al. (1988) − −
Levy et al. (1988) − −
lysis or polymerase chain reaction (PCR) ampliﬁcation. ± = weakly detectable.
from animals 586-3 and 586-4. PBMC were examined from animals 585-1, 585-2 and
-A/61E containing either the LTR of FeLV-945 (61E945L) or the SU gene and LTR of FeLV-
ruses FeLV-Aand FeLV-B (FeLV-A+B), or thehelpervirusesalone (FeLV-A+B). All animals
106 S. Ahmad, L.S. Levy / Virology 403 (2010) 103–110infected animals demonstrated the predicted ampliﬁcation product in
11 of 13 cases of thymic lymphoma (85%), in two of which FeLV-Bwas
not evident by Southern blot analysis (N65 and N67; Fig. 2B, Table 2).
Thus, the frequency of detection of FeLV-Bwas higher in experimental
as compared to natural thymic lymphomas (85% vs. 50%). While the
basis for this disparity is not understood, the difference may reﬂect
characteristics of the challenge virus. It is noteworthy that the
experimental thymic lymphomas resulted from infection with FeLV-
A/61E, or with a chimeric virus (61E/945L) in which only the LTR of
FeLV-945 was substituted into FeLV-A/61E. By comparison, the
naturally infected animals represented a cohort in which FeLV-945
was the predominant isolate (Chandhasin et al., 2004). Thus, the
difference in frequency of FeLV-B in natural vs. experimental thymic
lymphomas may reﬂect a reduced frequency or efﬁciency of
recombination in animals infected with FeLV-945, among other
variables including age or route of inoculation.
In 3 of 3 cases of experimentalmulticentric lymphoma (100%), the
predicted ampliﬁcation product was weakly demonstrated (Fig. 2B),
although no such demonstration was evident by Southern blot. PCR
ampliﬁcation further demonstrated the predicted product in feline
infectious peritonitis and in two healthy animals inoculated with
myc-containing FeLV in the presence of FeLV-B (Table 2). The weak
detection of FeLV-B in multicentric lymphomas suggests that FeLV-B
occurs at subclonal levels in those tumors, andmay indeed represent
a passenger rather than a causal agent of the disease. Considering
natural and experimental multicentric lymphomas together, FeLV-B
was detected by Southern blot in only 3 of 15 cases and was weakly
demonstrated by PCR in 3 additional cases. In contrast, when
considering natural and experimental thymic lymphomas together,
FeLV-B was detected by Southern blot in 11 of 17 cases and was
demonstrated by PCR in 2 additional cases. Thus, the frequency of
detection of FeLV-B was signiﬁcantly lower in multicentric lympho-
ma and other non-T-cell disease than in thymic lymphoma in both
naturally and experimentally infected animals (Tables 1 and 2). This
difference may reﬂect characteristics of the challenge virus, since
multicentric lymphomas were induced by FeLV-945 (in natural
infections) or by virus containing the envelope gene of FeLV-945 (in
experimental infections). By contrast, thymic lymphomas were
induced by experimental infection with FeLV-A/61E or virus
containing the envelope gene of FeLV-A/61E (Tables 1 and 2). The
FeLV genome present in thymic lymphomas in the natural cohort has
not yet been characterized. An alternative explanation is that the
difference may reﬂect the generally permissive environment for
recombination in T-cells, and/or the increased expression of
endogenous FeLV as recombination substrate in those cells (McDou-
gall et al., 1994). Taken together, these ﬁndings are consistent with
other reports in the literature regarding the frequent association of
FeLV-B with thymic lymphoma, and by implication, with a role for
FeLV-B in the induction of that disease (Bechtel et al., 1998; Jarrett,
1980, 1992; Roy-Burman, 1995; Sheets et al., 1993; Tsatsanis et al.,
1994). In contract, the infrequent detection and low levels of FeLV-B
in multicentric lymphoma do not support a role in the induction of
that disease.Nucleotide sequence analysis of FeLV-B recombinants and identiﬁcation
of recombination junctions
Gel-puriﬁed PCR products were further ampliﬁed using internal
primers, and the nucleotide sequence of products thus ampliﬁed wasFig. 3. Nucleotide sequence of the PCR ampliﬁcation products from tumor DNA of the indica
previously reported sequences of FeLV-945, FeLV-A/61E and FeLV-B/Gardner-Arnstein ar
indicated; (…) indicates sequence identity with CFE-6; (____) indicates deletion relative to
the positions of 34 nucleotide sequence differences in the ampliﬁcation products as compar
CFE-6. Also indicated about the sequence are recombination sites A–G, previously reporteddetermined from 5 experimentally induced thymic lymphomas (O3,
O4, O6, O23, and O24), 3 experimentally induced multicentric
lymphomas (N90, N91, and N92), a naturally occurring multicentric
lymphoma (1049), a naturally occurring thymic lymphoma (1110),
and an experimentally infected animal with feline infectious
peritonitis (586-4) (Fig. 3). The sequence of the ampliﬁcation
products was determined directly, without molecular cloning; thus,
the reported sequences represent the predominant species in each
sample. Other variants may indeed occur that were not detected by
this analysis. Of note, identical or nearly identical sequences were
detected as predominant among multiple, independent tumors of the
same type. For example, the predominant sequences from thymic
lymphomas O3, O4, O6, and O23 are identical or nearly identical, as
are those from natural and experimental multicentric lymphomas.
The sequence from thymic lymphoma O24 more closely resembled
those from multicentric lymphomas. For this reason, multiple
independent ampliﬁcations of O24 DNA were submitted for sequenc-
ing with conﬁrmatory results. To determine the recombination
junctions utilized for the generation of FeLV-B, sequences of the
ampliﬁcation products were compared to the endogenous FeLV
element CFE-6 and to the sequences of FeLV-B/Gardner-Arnstein,
FeLV-A/61E and FeLV-945. The identiﬁcation of 34 nucleotide
positions at which the ampliﬁcation products differed in sequence
from CFE-6 was used for identiﬁcation of the recombination junctions
(Fig. 3). This analysis was facilitated by a previous study in which a
limited number of sites were shown to be preferentially utilized for
recombination to generate FeLV-B during infection in vitro. The
preferential recombination sites, designated A–G (as shown in Fig. 3),
are locatedwithin a 275-bp region of the SU gene (Roy-Burman, 1995;
Sheets et al., 1992).
The present analysis demonstrated that FeLV-B/Gardner-Arn-
stein resulted from recombination at the previously designated site E,
as did 4 of 5 ampliﬁcation products from experimentally induced
thymic lymphoma samples (Fig. 3, position 8). The recombination
junction site used in thymic lymphoma O24 and multicentric
lymphomas N90, N91 and N92 was detected further downstream,
at 47 nucleotides beyond previously identiﬁed site G (Fig. 3, position
20). The recombination site used in naturally occurring thymic
lymphoma 1110 and multicentric lymphoma 1049, and in experi-
mentally infected cat 586-4 was identiﬁed at the 3′ end of the SU
gene, 96 nucleotides downstream from site G (Fig. 3, position 34).
Thus, FeLV-B proviruses from 4 of 5 thymic lymphomas utilized an
upstream recombination junction relative to those frommulticentric
lymphomas and therefore contained signiﬁcantlymore DNA from the
exogenous FeLV partner (Fig. 4). In the endogenous FeLV-derived
region upstream of the recombination sites, the analysis also
demonstrated seven nucleotide sequence changes in FeLV-B as
compared to CFE-6 (Fig. 3, sites 1–7), ﬁve of which resulted in amino
acid substitutions (Site 1, Asn to Ser; Site 2, Thr to Ile; Site 4, Pro to
Leu; Site 5, Ile to Thr; Site 6, Pro to Ser). These sequence differences
may represent mutational changes that were selected in the
generation of FeLV-B. It is noteworthy that the amino acid changes
are identical to those identiﬁed in an earlier analysis of FeLV-B
generation. In that study, the selection of these particular amino acid
changes was reported in natural and experimentally derived FeLV-B
isolates from diverse populations and geographic locations (Bechtel
et al., 1998). Taken together with the earlier study, our ﬁndings
support the hypothesis that recombinant viruses harboring the
speciﬁc amino acid changes are strongly selected during the disease
course.ted animals aligned with the sequence of endogenous FeLV-related provirus CFE-6. The
e aligned for comparison. Nucleotide sequence differences as compared to CFE-6 are
CFE-6; (//) indicates a break in the sequence shown. Indicated above the sequence are
ed to CFE-6. Those indicated with an asterisk (*) result in amino acid change relative to
to be preferred sites for crossover in the generation of FeLV-B (Sheets et al., 1992).
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Fig. 4. Schematic representation of the recombination junctions identiﬁed in the SU genes of FeLV-B viruses ampliﬁed from tumor DNA of the indicated animals. Depicted for
comparison are the SU genes of exogenous viruses FeLV-A/61E (solid bar) and FeLV-945 (gray bar) and endogenous FeLV-related provirus CFE-6 (open bar). A deletion within FeLV-
A/61E relative to CFE-6 is indicated (vv). Shown diagrammatically are the positions of previously identiﬁed preferred recombination sites A–G (Sheets et al., 1992). Also indicated is
the infectivity of genomic DNA for canine-D17 cells, presumably representing polytropic FeLV-B replication.
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The results of recombination site analysis demonstrated that
FeLV-B recombinants in thymic lymphomas contain less endogenous
FeLV sequence than do recombinants in multicentric lymphomas
(Fig. 4). As endogenous FeLV-related elements are defective and do
not encode infectious particles (McDougall et al., 1994), these
observations suggest that the inclusion of increasing amounts of
endogenous FeLV-derived sequence in the recombinants in multi-
centric lymphomas may have reduced their infectivity. To test this
possibility, genomic DNA (5 µg) of ﬁve experimentally induced
thymic lymphomas, three experimentally induced multicentric
lymphomas, one natural multicentric lymphoma, one natural thymic
lymphoma and one case of feline infectious peritonitis was
introduced by Lipofectamine Plus-mediated transfection for 4 h
into canine D-17 cells. Genomic DNA from D-17 cells infected with
FeLV-B/Gardner-Arnstein was included as a positive control. At
regular intervals thereafter for ﬁfteen days, the culture supernatant
was examined by p27Gag ELISA for the presence of FeLV particles. The
logic of this approach is that exogenous FeLV-A proviruses present in
genomic DNA samples would not be expected to replicate in canine
cells because of their ecotropic host range. Rather, considering the
expanded host range of FeLV-B that includes canine cells (Neil et al.,
1991), FeLV replication in this assay is assumed to result from
infectious FeLV-B proviruses in genomic DNA. The results demon-
strated infectious FeLV-B in FeLV-B/Gardner-Arnstein-infected D-17
cells and from four cases of thymic lymphoma, all of which utilized
recombination site E. Of the remaining samples, all of which utilized
recombination sites downstream of site G, none demonstrated
infectious virus (Fig. 4). These ﬁndings are consistent with an earlier
report that associated increasing endogenous SU content with
reduced infectivity of FeLV-B. Indeed, analysis of chimeric virus
constructs demonstrated lack of infectivity when most of the
recombinant SU gene was derived from CFE-6 (Pandey et al., 1991).
Among the natural recombinants examined in the present study was
that from thymic lymphoma 1110, which was the original source of
themyc oncogene-containing FeLV isolate designated LC-FeLV (Levy
et al., 1984). In this case, the rapid induction of lymphoma 1110 by an
oncogene-containing virus may have obviated the need for FeLV-B in
pathogenesis. In the remaining cases, including all multicentric
lymphomas examined, the lack of infectivity indicates that the FeLV-
B proviruses are defective and unlikely to have played a causal role in
disease induction.In summary, the data presented here conﬁrm previous demonstra-
tions of the frequent association of FeLV-B recombinants with thymic
lymphoma in the domestic cat (Jarrett, 1980, 1992; Roy-Burman, 1995;
Sheets et al., 1993; Tsatsanis et al., 1994), but show further that FeLV-B
recombinants occur infrequently and at low levels in non-T-cell diseases
including multicentric lymphoma (Figs. 1 and 2; Tables 1 and 2). It is
noteworthy that the multicentric lymphomas examined in the present
study were induced by FeLV-945, or by chimeric viruses containing the
LTR and SU gene of FeLV-945; thus, the absence of FeLV-B may reﬂect
infrequent or inefﬁcient recombination during FeLV-945 infection.
Further, while FeLV-B proviruses in the genomic DNA of thymic
lymphomas were generally infectious, those in the DNA of multicentric
lymphomas were not. The lack of infectivity may reﬂect the relatively
distal recombination junction and consequent abundance of endoge-
nously-derived sequence in the FeLV-B genomes (Figs. 3 and 4). The
ﬁndings indicate that the generation of recombinant FeLV-B is unlikely
to play a signiﬁcant role in the induction of non-T-cell disease including
multicentric lymphoma as evidenced by the infrequent detection and
low levels of FeLV-Band their lackof infectivity.Of note in this regard is a
fatal epidemic of FeLV infection recently described in the Florida
panther, in which clinical ﬁndings were consistent with FeLV-related
diseases of non-T-cell origin. The virus isolate, designated FeLV-Pco,was
shown to be closely related andperhaps identical to FeLV-945. Indeed, it
was suggested that the outbreakmayhave been caused by cross-species
transmission from a domestic cat, perhaps one infected with FeLV-945
(Brown et al., 2008). If recombination with endogenous FeLV-related
elements is not required for disease induction by FeLV-945, then wild
felids lacking such sequences in the genomemay indeed be susceptible
to infection and disease by this virus.Materials and methods
Tissues from natural and experimental infections in the domestic cat
The tissues of twenty-two naturally infected animals were
examined, representing the geographic and temporal cohort from
which FeLV-945 was originally identiﬁed (Chandhasin et al., 2004;
Levesque et al., 1990) and a gift of Dr. Murray Gardner. The cohort
included twelve cases ofmulticentric lymphoma, four cases of thymic
lymphoma, one case of myeloproliferative disease, one case of mast
cell leukemia, one case of feline infectious peritonitis, one case of
chronic glomerulonephritis, and two asymptomatic cases of FeLV-
109S. Ahmad, L.S. Levy / Virology 403 (2010) 103–110infected, healthy animals. An additional animal from the cohort was
shown to be FeLV-negative and healthy, and was examined as a
negative control. Twenty experimentally infected animals were
examined from several previous studies in which neonatal cats
were inoculated with one of the following viruses: (1) FeLV-A/61E, a
natural virus isolated from a complex of viruses linked to immuno-
deﬁciency disease when inoculated together (Donahue et al., 1991)
but causative of thymic lymphoma when inoculated alone (Chand-
hasin et al., 2005a,b); (2) LC-FeLV, a defective natural isolate from a
thymic lymphoma, demonstrated to contain themyc oncogene (Levy
et al., 1984). The defective nature of LC-FeLV was complemented by
growth in the presence of infectious helper viruses FeLV-A/Glasgow-
1 and FeLV-B/Gardner-Arnstein {an inoculum designated LC-FeLV
(FeLV-A+B)} (Levy et al., 1988); (3) Infectious FeLV-A+B helper
viruses in the absence of LC-FeLV (Levy et al., 1988); or (4) chimeric
viruses in which the LTR or the LTR and SU gene of the natural isolate,
FeLV-945, were substituted into FeLV-A/61E {designated 61E/945L
or 61E/945SL, respectively} (Chandhasin et al., 2005a,b). Tissues
from two mock-infected, healthy animals were also examined as
negative controls.Southern blot analysis for integrated FeLV proviruses
High molecular weight genomic DNA was prepared from cat
tissues and used for Southern blot analysis as previously described
(Chandhasin et al., 2005b). Brieﬂy, DNA (8 μg) was digested with
KpnI, electrophoresed in a 0.8% agarose gel and transferred to
nitrocellulose. Filters were hybridized for 18 h at 67 °C to radi-
olabeled probe B/S, a Sau3A fragment from the env gene of FeLV-B/
Gardner-Arnstein speciﬁc for the major classes of endogenous FeLV
that serve as substrates for recombination. By this approach, FeLV-B
is visualized in genomic DNA as a distinctive hybridizing fragment of
∼3.6-kb (Chandhasin et al., 2005b; Tsatsanis et al., 1994). Filterswere
similarly hybridized to a radiolabeled probe representing the U3
region of the LTR of exogenous FeLV. By this approach, clonally
integrated exogenous proviruses are visualized as host-virus junc-
tion fragments in tumor DNA. Endogenous FeLV-related elements in
feline DNA are weakly recognized as well (Levy et al., 1984).PCR ampliﬁcation of recombinant proviral DNA
Genomic DNA samples were ampliﬁed using forward (5′-
AACCCTGACAGACACCTTCCCTAC) and reverse (5′ GAGTGACCTAC-
CATCAACCCGA) primers speciﬁc for the endogenous FeLV-related
CFE-6 element (GenBank M25425.1) and exogenous FeLV-945
(GenBank AY662447), respectively. PCR was performed using
300 ng of genomic DNA in a 50 µl reaction with 200 ng of each
primer. An initial denaturation step at 95 °C for 5 min was followed
by 30 cycles of denaturation at 94 °C for 45 s, 62 °C for 45 s, and 72 °C
for 45 s with a ﬁnal extension for 10 min. PCR products were
analyzed by electrophoresis on 1% agarose gels and visualized by
ethidium bromide staining. To obtain sufﬁcient material for nucle-
otide sequence analysis, gel-puriﬁed PCR products were further
ampliﬁed using internal primers (5′-ATGTAGTGGAGGTGGTTGGTG
and 5-GGGGGGTTTGTTTGGTTGCTG) under the ampliﬁcation condi-
tions described above except that the annealing temperature was
57 °C. Ampliﬁcation productswere veriﬁed by nucleotide sequencing
directly, without molecular cloning. Nucleotide sequences thus
obtained have been deposited in GenBank (Accession numbers
GU434305–GU434315). Sequence data were compared for analysis
to the published sequences of FeLV-945 (AY662447), FeLV-A/61E
(M18248), FeLV-B/Gardner-Arnstein (K01209), and endogenous
element CFE-6 (M25425). Genomic DNA from FEA embryonic feline
ﬁbroblasts was used as a negative control for ampliﬁcation.DNA-mediated transfection and assay for productive infection
Canine D-17 cells (American Type Culture Collection, CCL-183)
were maintained in modiﬁed Eagle's medium (MEM) with non-
essential amino acids and 10% fetal bovine serum. Cells were grown to
40–50% conﬂuency in 6-well culture plates containing 2 ml of culture
medium. Genomic DNA (5 μg) of ﬁve experimentally induced thymic
lymphomas, three experimentally induced multicentric lymphomas,
one natural multicentric lymphoma, one natural thymic lymphoma
and one case of feline infectious peritonitis was introduced by
Lipofectamine Plus-mediated transfection (Invitrogen Corp; Carlsbad,
California, USA) for 4 h into D-17 cells. Genomic DNA from D-17 cells
infected with FeLV-B/Gardner-Arnstein was included as a positive
control. Cells were harvested two days later and transferred to a T-75
culture ﬂask. Culture supernatant was collected at regular intervals for
15 days thereafter and examined by p27Gag ELISA (Synbiotics
Corporation, San Diego, California) for the presence of FeLV particles.
A positive result was deﬁned in this analysis as an optical density
(A450) at least twice that of the negative control.Acknowledgments
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